U.S. Physical Therapy, Inc. (USPH)
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-09
$77.87-1.07%
Close 2026-09-09 · 1-day change
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-09
Intact: The reason to own it still holds.
U.S. Physical Therapy grows revenue about 8% yearly by adding clinics and partnerships. It acquired a 12-clinic practice with $12 million revenue. The company keeps paying dividends and manages debt to support growth. Strategic hospital partnerships aim to add $14 million EBITDA in 2027.
Earnings missed in Q1 2026 with a loss of $0.12 per share. Technology initiatives are early and unproven. Debt increased to support growth, which could pressure capital allocation. Hospital partnerships are still in early rollout and may not deliver expected gains.
The price is about 24% above our fair value near $58. Analysts expect roughly 8% revenue growth. Our model sees this growth as justified but the valuation is stretched, leaving limited margin for disappointment.
Breaks if: Dividend per share falls below $0.44 per share quarterly
Continue disciplined capital allocation with regular dividend payments and prudent use of credit facilities for growth and acquisitions.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a multi-year view on a company focused on growth through organic expansion and acquisitions. The current thesis state is intact, supported by strong recent financial performance, but there are concerns about management volatility and elevated risks.
The market currently prices USPH at an expensive valuation compared to its peers, reflecting a premium. There is an expectations gap, indicating that investors may be anticipating continued strong performance despite the company's recent challenges.
Fundamentals are likely to show continued revenue growth, driven by both organic expansion and acquisitions. However, there is a near-term risk of missing earnings expectations, as the company has a history of recent earnings misses.
The thesis hinges on management's ability to maintain guidance and execute on growth strategies, particularly in light of potential economic headwinds. Additionally, the performance of sector bellwethers and the overall healthcare sector will be critical for USPH's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss has negatively impacted the outlook. This suggests that the company's performance may not meet market expectations moving forward.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. The company declared a consistent quarterly dividend of $0.46 per share in Q1 and Q2 2026. The credit facility was upsized to $450 million with borrowings increasing from $162 million at 2025-Q4 to $221 million at 2026-Q2. Management reaffirmed full year 2026 adjusted EBITDA guidance of $102 million to $106 million. The trajectory shows disciplined capital allocation supporting growth and shareholder returns.
“Board declared quarterly dividend of $0.46 payable September 11, 2026; reaffirmed 2026 adjusted EBITDA guidance of $102M to $106M.”
“Reaffirmed full year 2026 adjusted EBITDA guidance of $102 million to $106 million; upsized $450 million credit facility announced.”
“Declared quarterly dividend of $0.46; credit facility with $30.5 million drawn; ended quarter with $35.6 million cash.”
Breaks if: Hospital partnership EBITDA contribution falls below $10 million in 2027
Expand hospital affiliations to increase patient volume, improve margins, and accelerate growth in key markets.
Stated as a priority in 3 of last 3 quarters. Hospital affiliation revenue contributed $5.6 million in 2026-Q2. The company transitioned 31 clinics in Q2 and expects remaining 39 clinics to integrate in Q3. Strategic hospital partnerships like NYU and Gulf Coast are expected to contribute at least $14 million EBITDA in 2027. The trajectory shows active rollout and growing contribution from hospital affiliations.
“Transition of NYU-affiliated clinics has gone very well... Hospital affiliation rollout contributed $5.6 million revenue.”
“Strong investment and effort to create opportunities with large hospital systems including NYU and Gulf Coast region.”
“Announced two significant hospital arrangements... Strategic relationships will phase-in mid-year 2026.”
Breaks if: YoY revenue growth falls below 6% next year
Continue to grow revenue by expanding clinic visits, acquiring new clinics, and increasing patient volume including hospital affiliations.
Stated as a priority in 3 of last 3 quarters. Revenue grew from $168 million in 2026-Q1 to $214 million in 2026-Q2, an 8.5% increase. Visits per clinic per day reached a record 33.5 in 2026-Q2. The company completed multiple acquisitions including a 12-clinic practice generating $12 million annual revenue. The trajectory is delivering consistent growth through organic expansion and acquisitions.
“Visits per clinic per day were at an all-time high this quarter at 33.5 per day... We acquired a twelve-clinic physical therapy practice...”
“Revenue increase in physical therapy of 7.2%, with the 2.5% same-store increase... We completed two significant acquisitions in the first quarter.”
“Demand continued unabated... We made several acquisitions... We announced two significant hospital arrangements.”
Breaks if: Technology initiatives fail to launch or show no efficiency gains by end 2026
In the next 1 to 3 years, USPH's performance will depend on its execution of growth strategies and external economic factors. Not investment advice.